Heterogeneity of FLT3 mutant clones and polyclonal architecture with respect to FLT3-ITD and FLT3-TKD have been shown by single-cell sequencing of AML samples from patients who relapsed during quizartinib treatment [32]. The gene discussed is FLT3; the disease is acute myeloid leukemia.